# US 2024/0003871 A1 · Ipsc-derived astrocytes and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0003871 A1
- Document ID: US20240003871A1
- Status: Published application
- Kind: A1
- Application number: 18/344,703
- Filed: 2023-06-29
- Published: 2024-01-04
- Earliest claimed: 2022-06-29
- Assignees: FUJIFILM Cellular Dynamics, Inc.; FUJIFILM Holdings America Corporation
- Applicants: FUJIFILM Cellular Dynamics, Inc.; FUJIFILM Holdings America Corporation
- Inventors: Deepika RAJESH; Christie MUNN; Sarah BURTON; Ali FATHI; Rachel LEWIS; Robert BRADLEY; Jing LIU
- Web page: https://patentgrep.com/patent/US20240003871A1

## CPC

- G01N 33/5058: {Neurological cells}
- C12N 5/0622: {Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells}
- C12N 2500/90: Serum-free medium, which may still contain naturally-sourced components
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/13: Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
- C12N 2501/2301: Interleukin-1 (IL-1)
- C12N 2501/235: Leukemia inhibitory factor [LIF]
- C12N 2501/25: Tumour necrosing factors [TNF]
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2502/08: cells of the nervous system
- C12N 2502/086: glial cells
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2513/00: 3D culture
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides method for producing neural precursor cells with a glial bias from induced pluripotent cells and further differentiating the neural precursor cells to astrocytes. Further provided herein are methods for the use of the astrocytes for screening assays, models mimicking the human brain, and cell therapy.

## Claims

### Claim 1

An in vitro method for producing astrocytes from induced pluripotent stem cells (iPSCs) comprising:
(a) obtaining a starting population of neural precursor cells (NPCs) derived from iPSCs;
(b) culturing the NPCs in the presence of at least one leukemia inhibitory factor (LIF) receptor ligand for a period of time sufficient to produce astrocyte progenitor cells (APCs); and
(c) further culturing the APCs in the presence of at least one LIF receptor ligand and lipid concentrate for a period of time sufficient to produce a population of astrocytes.

### Claim 2 (depends on 1)

The method of claim 1, wherein the iPSCs are cultured in serum free defined media.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the method is good-manufacturing practice (GMP) compliant.

### Claim 4 (depends on 1, 2, 3)

The method of any of claims 1-3, wherein one or more of steps (a)-(d) are performed under xeno-free conditions, feeder-free conditions, and/or conditioned-media free conditions.

### Claim 5 (depends on 1, 2, 3)

The method of any of claims 1-3, wherein each of steps (a)-(d) are performed under xeno-free conditions, feeder-free conditions, and/or conditioned-media free conditions.

### Claim 6 (depends on 1, 2, 3)

The method of any of claims 1-3, wherein each of steps (a)-(d) are performed under defined conditions.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any of claims 1-6, wherein the iPSCs are human iPSCs.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any of claims 1-7, wherein obtaining the starting population of NPCs comprises:
(a) culturing iPSCs on an extracellular matrix (ECM) protein coated surface in the presence of a ROCK inhibitor;
(b) further culturing the iPSCs in the absence of a ROCK inhibitor or blebbistatin;
(c) pre-conditioning the iPSCs in the presence of a GSK3 inhibitor;
(d) differentiating the iPSCs to a population of NPCs.

### Claim 9 (depends on 8)

The method of claim 8, wherein the ECM protein is laminin, fibronectin, vitronectin, MATRIGEL™, tenascin, entactin, thrombospondin, elastin, gelatin, and/or collagen.

### Claim 10 (depends on 8)

The method of claim 8, wherein the ECM protein is basement membrane extract (BME) purified from murine Engelbreth-Holm-Swarm tumor

### Claim 11 (depends on 8)

The method of claim 8, wherein the ECM protein is MATRIGEL™, laminin, or vitronectin.

### Claim 12 (depends on 8)

The method of claim 8, wherein the extracellular matrix protein is MATRIGEL™.

### Claim 13 (depends on 8, 9, 10, 11, 12)

The method of any of claims 8-12, wherein the method does not comprise inhibition of SMAD signaling.

### Claim 14 (depends on 8, 9, 10, 11, 12, 13)

The method of any of claims 8-13, wherein steps (a)-(b) are performed under hypoxic conditions.

### Claim 15 (depends on 8, 9, 10, 11, 12, 13, 14)

The method of any of claims 8-14, wherein the culturing of steps (a)-(b) is further defined as adherent 2-dimensional culture.

### Claim 16 (depends on 8, 9, 10, 11, 12, 13, 14, 15)

The method of any of claims 8-15, wherein step (a) is for about 24 hours.

### Claim 17 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any of claims 8-16, wherein step (b) is for about 48 hours.

### Claim 18 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any of claims 8-17, wherein the ROCK inhibitor is H1152.

### Claim 19 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any of claims 8-18, wherein step (c) is performed under normoxic conditions.

### Claim 20 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any of claims 8-19, wherein step (c) is performed for about 72 hours.

### Claim 21 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any of claims 8-20, wherein the GSK3 inhibitor is CHIR99021, BIO, or SB-216763.

### Claim 22 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any of claims 8-20, wherein the GSK3 inhibitor is CHIR99021.

### Claim 23 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any of claims 8-22, wherein step (d) comprises the formation of aggregates in the presence of a ROCK inhibitor.

### Claim 24 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any of claims 8-23, wherein the cell culture is a three-dimensional (3D) culture.

### Claim 25 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any of claims 8-24, wherein step (d) comprises culture on ultra-low attachment plates, spinners, or bioreactors.

### Claim 26 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any of claims 8-25, wherein step (d) is for about 8 days.

### Claim 27 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any of claims 8-26, wherein the NPCs express CD24, CD184, and CD271.

### Claim 28 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any of claims 8-27, further comprising detecting expression of CD56, CD15, Sox1, Nestin, 03-Tubulin, Microglobulin, and/or Pax-6 in the population NPCs.

### Claim 29 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any of claims 8-28, wherein the population of NPCs are at least 70% percent positive for CD24 and Nestin.

### Claim 30 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any of claims 8-29, wherein the NPCs express Pax6 and Nestin.

### Claim 31 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any of claims 8-30, wherein the APCs have decreased expression of SSEA-4 and TRA-1-60 as compared to the iPSCs after step (b).

### Claim 32 (depends on 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any of claims 8-31, wherein the NPCs are cryopreserved.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any of claims 1-32, wherein the iPSCs are derived from a healthy donor.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any of claims 1-33, wherein the iPSCs are derived from a donor with a disease.

### Claim 35 (depends on 34)

The method of claim 34, wherein the disease is Alexander's disease or leukodystrophy.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any of claims 1-35, wherein the iPSCs comprise a disruption in TREM2, APOE, Methyl-CpG Binding Protein 2 (MeCP2), and/or Alpha-synuclein (SCNA).

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any of claims 1-35, wherein the astrocytes are end stage astrocytes positive for CD44, S100b, NFIX, GLAST, and/or GFAP.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any of claims 1-35, wherein the astrocytes are positive for SSEA4 and CD44.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any of claims 1-35, wherein at least 30% of the population of astrocytes is positive for SSEA4 and CD44.

### Claim 40 (depends on 37)

The method of claim 37, wherein the astrocytes have functional glutamate uptake and/or development of a neural network.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method of any of claims 1-40, wherein the at least one LIF receptor ligand is Leukemia-Inhibitory Factor protein (LIF), Ciliary-Derived Neurotrophic Factor protein (CNTF), oncostatin-M protein (OSM), and/or cardiotrophin 1 (CT-1).

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method any of claims 1-41, wherein step (b) further comprises culturing in the presence of lipid concentrate, EGF, JAGG1, and/or DLL1.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any of claims 1-42, wherein step (b) comprises culturing in the presence of LIF, CNTF, OSM, JAGG1, lipid concentrate, and EGF.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any of claims 1-42, wherein step (b) comprises culturing in the presence of LIF, CNTF, OSM, DLL1, lipid concentrate, and EGF.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any of claims 1-42, wherein step (b) comprises culturing in the presence of LIF, CNTF, OSM, JAGG1, DLL1, lipid concentrate, and EGF.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any of claims 1-42, wherein step (b) comprises culturing in the presence of LIF, CNTF, OSM, JAGG1, CT1, lipid concentrate, and EGF.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any of claims 1-42, wherein step (b) comprises culturing in the presence of LIF, CNTF, OSM, DLL1, CT1, lipid concentrate, and EGF.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any of claims 1-47, wherein the APCs are cultured in the presence of LIF, CNTF, oncostatin-M, and/or CT-1.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The method of any of claims 1-48, wherein the APCs are cultured in the presence of LIF and CNTF.

### Claim 50 (depends on 41, 42, 43, 44, 45, 46, 47, 48, 49)

The method of any of claims 41-49, wherein LIF, CNTF, oncostatin-M and/or CT-1 are present at a concentration of about 1-20 ng/mL.

### Claim 51 (depends on 41, 42, 43, 44, 45, 46, 47, 48, 49)

The method of any of claims 41-49, wherein LIF, CNTF, oncostatin-M and/or CT-1 are present at a concentration of about 10 ng/mL.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The method of any of claims 1-51, wherein step (b) comprises culturing the NPCs on a Geltrex-coated surface.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method of any of claims 1-52, wherein step (b) is for about 2 weeks.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The method of any of claims 1-53, wherein step (c) comprises culturing the cells on a vitronectin-coated surface.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any of claims 1-54, wherein the lipid concentrate is a chemically defined lipid concentrate.

### Claim 56 (depends on 55)

The method of claim 55, wherein the chemically defined lipid concentrate comprises saturated and unsaturated fatty acids.

### Claim 57 (depends on 55)

The method of claim 55, wherein the chemically defined lipid concentrate comprises arachidonic acid, cholesterol, DL-alpha-Tocopherol Acetate, linoleic acid, linolenic acid, myristic acid, oleic acid, palmitic acid, palmitoleic acid, and stearic acid.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The method of any of claims 1-55, wherein step (c) is for about 4 weeks to 7 weeks.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The method of any of claims 1-58, wherein the astrocytes express CD44, NFIX, and/or GFAP.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any of claims 1-59, wherein the astrocytes express CD56, S100B, CD44, GFAP, NFIX, and/or GLAST.

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The method of any of claims 1-60, wherein the population of astrocytes is at least 80% positive for S100B, CD44, and/or NFIX.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The method of any of claims 1-61, wherein the population of astrocytes is at least 30% positive for CD56 and/or GFAP.

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The method of any of claims 1-62, wherein the astrocytes maintain network activity and uptake excess glutamate.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any of claims 1-63, wherein the astrocytes secrete IL-1ra, IL-6, IL-8 (CXCL8), IL-10, CCL5 (RANTES), CCL7, CCL20, CXCL1, CXCL2 and/or CXCL5 after stimulation with IL-1α and/or TNFα.

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any of claims 1-63, wherein the astrocytes secrete IL-1ra, IL-6, IL-8 (CXCL8), IL-10, CCL5 (RANTES), CCL7, CCL20, CXCL1, CXCL2 and CXCL5 after stimulation with IL-1α and/or TNFα.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

A pharmaceutical composition comprising as astrocyte cell population produced according to any of claims 1-63 and a pharmaceutically acceptable carrier.

### Claim 67 (depends on 66)

The composition of claim 66, wherein the astrocyte cell population is at least 30% positive for SSEA4 and CD44.

### Claim 68 (depends on 66)

The composition of claim 66, wherein the astrocyte cell population is at least 45% positive for SSEA4 and CD44.

### Claim 69

A composition comprising an astrocyte cell population at least 70% positive for S100B, CD44, and/or NFIX, wherein the astrocyte cell population is differentiated from iPSCs.

### Claim 70 (depends on 69)

The composition of claim 69, wherein the astrocyte cell population is at least 80% positive for S100B, CD44, and/or NFIX.

### Claim 71 (depends on 69)

The composition of claim 69, wherein the astrocyte cell population is at least 30% positive for SSEA4 and CD44.

### Claim 72 (depends on 69)

The composition of claim 69, wherein the astrocyte cell population is at least 45% positive for SSEA4 and CD44.

### Claim 73 (depends on 69)

The composition of claim 69, further comprising neurons.

### Claim 74 (depends on 66, 67, 68, 69, 70, 71, 72, 73)

A method for screening a test compound comprising introducing the test compound to an astrocyte cell population of any of claims 66-73.

### Claim 75 (depends on 74)

The method of claim 74, further comprising measuring astrocyte viability and/or function.

### Claim 76 (depends on 66, 67, 68, 69, 70, 71, 72, 73)

Use of the composition of any of claims 66-73 as a model for neurodegenerative disease or injury.

### Claim 77 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

A co-culture comprising astrocytes and/or neural precursor cells produced by the method of any of claims 1-63, endothelial cells, and pericytes.

### Claim 78 (depends on 77)

Use of the co-culture of claim 77 to mimic human brain development or neurodegeneration.

### Claim 79 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

A kit comprising astrocytes produced by the method of any of claims 1-63.

### Claim 80 (depends on 79)

The kit of claim 79, further comprising endothelial cells and/or pericytes.

### Claim 81 (depends on 77)

A model of neurodegeneration comprising the co-culture of claim 77.

### Claim 82 (depends on 66, 67, 68, 69, 70, 71, 72, 73)

A method for treating a neurodegenerative disease comprising administering an effective amount of the astrocyte cell composition of any of claims 66-73 to a subject.

### Claim 83 (depends on 82)

The method of claim 82, wherein the disease is Alexander's disease or leukodystrophy.
